Overview
Aviir is a venture-funded biotechnology company developing cutting-edge, convenient diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology draws on years of research at Stanford University, and combines the scientific founders’ deep understanding of disease marker proteins and advanced biostatistics. Aviir is pursuing an aggressive commercialization strategy and initial products are expected to reach the market within 24 months. The Aviir team includes the founding scientists and highly experienced management.